The number of Ozempic intestinal blockage and obstruction cases, including ileus cases, that have been reported to the FDA during the first 6 months of 2023 was covered in this September 28, 2023 article, “FDA Adds New Warning for Ileus to Semaglutide (Ozempic) Label”, published September 28, 2023, on the HCPLive® website:
According to the US FDA’s Adverse Events Reporting System (FAERS) public dashboard, there have been 2951 total cases of adverse events associated with use of Ozempic during 2023 as of June 30, 2023. The majority of these cases are gastrointestinal-related events, which account for 1274 of the 2951 total cases.
Within the FAERS public dashboard, there were 6 total cases of ileus reported with use of [Ozempic], with 2 resulting in hospitalization. Of note, the number of cases reported so far in 2023 is more than double the total number of cases reported in 2019.
In September 2023 the Ozempic (semaglutide) drug label was updated to inform doctors and patients that adverse reaction reports concerning ileus, a gastrointestinal disorder, have been received for semaglutide during the time since Ozempic was first approved by the FDA in 2017. This September 2023 Ozempic label change can be found in part “6.3 Postmarketing Experience” of the Ozempic Full Prescribing Information document (“Revised: 9/2023” version).
We will watch for more information on Ozempic intestinal blockage and obstruction cases, including ileus cases, in the medical literature and from the FDA as well as other drug regulators worldwide.
At the present time, we are investigating Ozempic intestinal blockage and obstruction cases where there has been a diagnosis of gastroparesis, gastric stasis, or stomach paralysis as possible drug injury lawsuits to be filed against Novo Nordisk, the responsible pharmaceutical company. We are also looking into similar cases involving Rybelsus or Wegovy, two other semaglutide drugs from Novo Nordisk. All three of these drugs, Ozempic, Rybelsus, and Wegovy, are being used more and more for weight-loss purposes, as has been reported by the mainstream media during this past year.[Read article in full at original source]
Strictly Confidential, No Obligation